Biomarkers of operational tolerance in solid organ transplantation

Expert Opinion on Medical Diagnostics

Volumn 6, Issue 4, 2012, Pages 281-293

  Heidt, Sebastiaan ^a,b   Wood, Kathryn J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute rejection; Immunosuppressive drug withdrawal; Kidney transplantation; Liver transplantation; Tolerance fingerprint

Indexed keywords

BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

B LYMPHOCYTE; DRUG WITHDRAWAL; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LONG TERM CARE; ORGAN TRANSPLANTATION; PATIENT MONITORING; PATIENT SAFETY; REGULATORY T LYMPHOCYTE; REVIEW;

EID: 84863106156     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2012.680019     Document Type: Review

References (85)

1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357(25):2601-14
2. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004;4(6):905-13
3. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349(10):931-40
4. Bodziak KA, Hricik DE. New-onset diabetes mellitus after solid organ transplantation. Transpl Int 2009;22(5):519-30
5. Kingsley CI, Nadig SN, Wood KJ. Transplantation tolerance: lessons from experimental rodent models. Transpl Int 2007;20(10):828-41
6. Auchincloss H Jr. In search of the elusive Holy Grail: the mechanisms and prospects for achieving clinical transplantation tolerance. Am J Transplant 2001;1(1):6-12
7. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89-95
8. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008;8(4):753-60
9. Goldman M, Wood K. Transplantation research: will we ever reach the holy grail? Transplantation 2009;87(9 Suppl):S99-100
10. Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008;118(8):2845-57
11. Brouard S, Le Bars A, Dufay A, et al. Identification of a gene expression profile associated with operational tolerance among a selected group of stable kidney transplant patients. Transpl Int 2011;24(6):536-47
12. Orlando G, Soker S, Wood K. Operational tolerance after liver transplantation. J Hepatol 2009;50(6):1247-57
13. Opelz G, Dohler B. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 2008;86(3):371-6
14. Starzl TE. The 'privileged' liver and hepatic tolerogenicity. Liver transpl 2001;7(10):918-20
15. Ramos HC, Reyes J, Abu-Elmagd K, et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 1995;59(2):212-17
16. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997; 63(2):243-9
17. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001;72(3):449-54
18. Tzakis AG, Reyes J, Zeevi A, et al. Early tolerance in pediatric liver allograft recipients. J Pediatr Surg 1994;29(6):754-6
19. Li Y, Koshiba T, Yoshizawa A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004; 4(12):2118-25
20. Martinez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operationaltolerance in liver transplantation. Am J Transplant 2007;7(2):309-19
21. Li L, Wozniak LJ, Rodder S, et al. A common peripheral blood gene set for diagnosis of operational tolerance in pediatric and adult liver transplantation. Am J Transplant 2012; doi: 10.1111/j.1600-6143.2011.03928.x
22. Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 2007;17(2):94-7
23. Puig-Pey I, Bohne F, Benitez C, et al. Characterization of gammadelta T cell subsets in organ transplantation. Transpl Int 2010;23(10):1045-55
24. Mazariegos GV, Sindhi R, Thomson AW, Marcos A. Clinical tolerance following liver transplantation: long term results and future prospects. Transpl Immunol 2007;17(2):114-19
25. Pons JA, Revilla-Nuin B, Baroja-Mazo A, et al. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation 2008;86(10):1370-8
26. Tokita D, Mazariegos GV, Zahorchak AF, et al. High PD-L1/ CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation 2008;85(3):369-77
27. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003;3(3):199-210
28. Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010;16(7):809-13
29. Castellaneta A, Mazariegos GV, Nayyar N, et al. HLA-G level on monocytoid dendritic cells correlates with regulatory T-cell Foxp3 expression in liver transplant tolerance. Transplantation 2011;91(10):1132-40
30. Li Y, Zhao X, Cheng D, et al. The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation 2008;86(12):1837-43
31. Kovats S, Main EK, Librach C, et al. A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990;248(4952):220-3
32. Deschaseaux F, Delgado D, Pistoia V, et al. HLA-G in organ transplantation: towards clinical applications. Cell Mol Life Sci 2011;68(3):397-404
33. Zarkhin V, Talisetti A, Li L, et al. Expression of soluble HLA-G identifies favorable outcomes in liver transplant recipients. Transplantation 2010;90(9):1000-5
34. Mazariegos GV, Zahorchak AF, Reyes J, et al. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant 2003;3(6):689-96
35. Mazariegos GV, Zahorchak AF, Reyes J, et al. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant 2005;5(2):314-22
36. Mueller DL. Mechanisms maintaining peripheral tolerance. Nat immunol 2010;11(1):21-7
37. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010;120(6):1848-61
38. Newell KA, Asare A, Kirk AD, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010;120(6):1836-47
39. Lozano JJ, Pallier A, Martinez-Llordella M, et al. Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients. Am J Transplant 2011;11(9):1916-26
40. Louis S, Braudeau C, Giral M, et al. Contrasting CD25hiCD4+T cells/ FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006;81(3):398-407
41. Pallier A, Hillion S, Danger R, et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010;78(5):503-13
42. Liu C, Noorchashm H, Sutter JA, et al. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med 2007;13(11):1295-8
43. Zarkhin V, Lovelace PA, Li L, et al. Phenotypic evaluation of B-cell subsets after rituximab for treatment of acute renal allograft rejection in pediatric recipients. Transplantation 2011;91(9):1010-18
44. Blair PA, Norena LY, Flores-Borja F, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010;32(1):129-40
45. Chong AS, Sciammas R. Matchmaking the B-cell Signature of Tolerance to Regulatory B cells. Am J Transplant 2011;11(12):2555-60
46. Matsushita T, Yanaba K, Bouaziz JD, et al. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008; 118(10):3420-30
47. Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011;117(2):530-41
48. Le Texier L, Thebault P, Lavault A, et al. Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile. Am J Transplant 2011;11(3):429-38
49. Roussey-Kesler G, Giral M, Moreau A, et al. Clinical operational tolerance after kidney transplantation. Am J Transplant 2006;6(4):736-46
50. Brouard S, Dupont A, Giral M, et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transplant 2005;5(2):330-40
51. Baeten D, Louis S, Braud C, et al. Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol 2006;17(1):294-304
52. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007;104(39):15448-53
53. Sawitzki B, Bushell A, Steger U, et al. Identification of gene markers for the prediction of allograft rejection or permanent acceptance. Am J Transplant 2007;7(5):1091-102
54. Long ET, Baker S, Oliveira V, et al. Alpha-1,2-mannosidase and hence N-glycosylation are required for regulatory T cell migration and allograft tolerance in mice. PLoS One 2010;5(1):e8894
55. Haynes LD, Jankowska-Gan E, Sheka A, et al. Donor-specific indirect pathway analysis reveals a B-cell-independent signature which reflects outcomes in kidney transplant recipients. Am J Transplant 2012;12(3):640-8
56. Jones ND, Turvey SE, Van Maurik A, et al. Differential susceptibility of heart, skin, and islet allografts to T cell-mediated rejection. J immunol 2001;166(4):2824-30
57. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006;6(8):1774-80
58. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008;358(4):353-61
59. Scandling JD, Busque S, Shizuru JA, et al. Induced immune tolerance for kidney transplantation. N Engl J Med 2011;365(14):1359-60
60. Neujahr D, Turka LA. Lymphocyte depletion as a barrier to immunological tolerance. Contrib Nephrol 2005;146:65-72
61. Shapiro R, Jordan ML, Basu A, et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg 2003;238(4):520-5; discussion 5-7
62. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or campath. J Am Coll Surg 2005;200(4):505-15; quiz A59-61
63. D'Addio F, Yuan X, Habicht A, et al. A novel clinically relevant approach to tip the balance toward regulation in stringent transplant model. Transplantation 2010;90(3):260-9
64. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998;351(9117):1701-2
65. Calne R, Watson CJ. Some observations on prope tolerance. Curr Opin Organ Transplant 2011;16(4):353-8
66. Noris M, Casiraghi F, Todeschini M, et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007;18(3):1007-18
67. Bloom DD, Chang Z, Fechner JH, et al. CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with campath-1H. Am J Transplant 2008;8(4):793-802
68. Pascual J, Bloom D, Torrealba J, et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. Am J Transplant 2008;8(7):1529-36
69. Trzonkowski P, Zilvetti M, Chapman S, et al. Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 2008;8(2):338-47
70. Heidt S, Hester J, Shankar S, et al. B-Cell repopulation after alemtuzumab induction - transient increase in transitional B cells and long-term dominance of naïve B cells. Am J Transplant 2012; doi: 10.1111/j.1600- 6143.2012.04012.x
71. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with memory-like phenotype are the dominant cell type following antibody-mediated -cell depletion. Am J Transplant 2005;5(3):465-74
72. Trzonkowski P, Zilvetti M, Friend P, Wood KJ. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. Transplantation 2006;82(10):1342-51
73. Knechtle SJ, Pascual J, Bloom DD, et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am J Transplant 2009;9(5):1087-98
74. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009;9(1):201-9
75. Heidt S, Roelen DL, Vergunst M, et al. Bortezomib affects the function of human B cells: possible implications for desensitization protocols. Clin Transpl 2009;387-92
76. Trivedi HL, Terasaki PI, Feroz A, et al. Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients. Transplantation 2010;90(2):221-2
77. Terasaki PI. The beneficial transfusion effect on kidney graft survival attributed to clonal deletion. Transplantation 1984;37(2):119-25
78. Dankers MK, Witvliet MD, Roelen DL, et al. The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens. Transplantation 2004;77(8):1236-9
79. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity providesa potent barrier to transplantation tolerance. J Clin Invest 2003;111(12):1887-95
80. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol 2012;30:221-41
81. Ballet C, Roussey-Kesler G, Aubin JT, et al. Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft. Am J Transplant 2006;6(11):2796-801
82. Welsh RM, Markees TG, Woda BA, et al. Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. J Virol 2000;74(5):2210-18
83. Issa F, Hester J, Goto R, et al. Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation 2010;90(12):1321-7
84. Wood KJ, Goto R. Mechanisms of rejection: current perspectives. Transplantation 2012;93(1):1-10
85. Heidt S, San Segundo D, Shankar S, et al. Peripheral blood sampling for the detection of allograft rejection: biomarker identification and validation. Transplantation 2011;92(1):1-9